Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low hemoglobin predicts high-platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Verdoia M, Rolla R, Pergolini P, Gioscia R, Nardin M, Negro F, Viglione F, Suryapranata H, Kedhi E, De Luca G; Novara Atherosclerosis Study Group (NAS). Verdoia M, et al. Among authors: gioscia r. Catheter Cardiovasc Interv. 2021 Dec 1;98(7):1309-1316. doi: 10.1002/ccd.29512. Epub 2021 Feb 1. Catheter Cardiovasc Interv. 2021. PMID: 33527669
Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy.
Verdoia M, Pergolini P, Nardin M, Rolla R, Negro F, Gioscia R, Fierro N, Saghir Afifeh AM, Viglione F, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Verdoia M, et al. Among authors: gioscia r. Cardiovasc Revasc Med. 2020 Sep;21(9):1144-1149. doi: 10.1016/j.carrev.2020.02.007. Epub 2020 Feb 13. Cardiovasc Revasc Med. 2020. PMID: 32085942
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Verdoia M, Nardin M, Gioscia R, Negro F, Marcolongo M, Suryapranata H, Kedhi E, De Luca G; Novara Atherosclerosis Study Group (NAS). Verdoia M, et al. Among authors: gioscia r. Vascul Pharmacol. 2020 Sep;132:106765. doi: 10.1016/j.vph.2020.106765. Epub 2020 Jul 16. Vascul Pharmacol. 2020. PMID: 32681888
Prognostic impact of Vitamin D deficiency in patients with coronary artery disease undergoing percutaneous coronary intervention.
Verdoia M, Nardin M, Rolla R, Negro F, Gioscia R, Afifeh AMS, Viglione F, Suryapranata H, Marcolongo M, De Luca G; Novara Atherosclerosis Study Group (NAS). Verdoia M, et al. Among authors: gioscia r. Eur J Intern Med. 2021 Jan;83:62-67. doi: 10.1016/j.ejim.2020.08.016. Epub 2020 Aug 20. Eur J Intern Med. 2021. PMID: 32830035
Vitamin D levels condition the outcome benefits of renin-angiotensin system inhibitors (RASI) among patients undergoing percutaneous coronary intervention.
Verdoia M, Nardin M, Rolla R, Negro F, Gioscia R, Saghir Afifeh AM, Viglione F, Suryapranata H, Marcolongo M, De Luca G; Novara Atherosclerosis Study Group (NAS). Verdoia M, et al. Among authors: gioscia r. Pharmacol Res. 2020 Oct;160:105158. doi: 10.1016/j.phrs.2020.105158. Epub 2020 Aug 22. Pharmacol Res. 2020. PMID: 32841717
Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor.
Verdoia M, Tonon F, Gioscia R, Nardin M, Fierro N, Sagazio E, Negro F, Pergolini P, Rolla R, De Luca G; Novara Atherosclerosis Study Group (NAS). Verdoia M, et al. Among authors: gioscia r. Thromb Res. 2020 Dec;196:231-237. doi: 10.1016/j.thromres.2020.09.006. Epub 2020 Sep 3. Thromb Res. 2020. PMID: 32916566
32 results